Gene Therapy for Cancer

por Schepelmann, S, Springer, C J
Publicado 2008

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors

por Hooper, A., Zambon, A., Springer, C. J.
Publicado 2016

Internal parasitic burdens in brown rats (Rattus norvegicus) from Grenada, West Indies

por Coomansingh-Springer, C., Vishakha, V., Acuna, A. Montanez, Armstrong, E., Sharma, R.N.
Publicado 2019

A cytotoxic agent can be generated selectively at cancer sites.

por Bagshawe, K. D., Springer, C. J., Searle, F., Antoniw, P., Sharma, S. K., Melton, R. G., Sherwood, R. F.
Publicado 1988

Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.

por Antoniw, P., Springer, C. J., Bagshawe, K. D., Searle, F., Melton, R. G., Rogers, G. T., Burke, P. J., Sherwood, R. F.
Publicado 1990

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

por Turajlic, S., Furney, S. J., Stamp, G., Rana, S., Ricken, G., Oduko, Y., Saturno, G., Springer, C., Hayes, A., Gore, M., Larkin, J., Marais, R.
Publicado 2014

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.

por Blakey, D. C., Davies, D. H., Dowell, R. I., East, S. J., Burke, P. J., Sharma, S. K., Springer, C. J., Mauger, A. B., Melton, R. G.
Publicado 1995

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs

por Spooner, R A, Friedlos, F, Maycroft, K, Stribbling, S M, Roussel, J, Brueggen, J, Stolz, B, O'Reilly, T, Wood, J, Matter, A, Marais, R, Springer, C J
Publicado 2003

Deletion of Tbc1d4/As160 abrogates cardiac glucose uptake and increases myocardial damage after ischemia/reperfusion

por Binsch, C., Barbosa, D. M., Hansen-Dille, G., Hubert, M., Hodge, S. M., Kolasa, M., Jeruschke, K., Weiß, J., Springer, C., Gorressen, S., Fischer, J. W., Lienhard, M., Herwig, R., Börno, S., Timmermann, B., Cremer, A. L., Backes, H., Chadt, A., Al-Hasani, H.
Publicado 2023

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

por Francis, R J, Sharma, S K, Springer, C, Green, A J, Hope-Stone, L D, Sena, L, Martin, J, Adamson, K L, Robbins, A, Gumbrell, L, O'Malley, D, Tsiompanou, E, Shahbakhti, H, Webley, S, Hochhauser, D, Hilson, A J, Blakey, D, Begent, R H J
Publicado 2002

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers

por Saturno, G., Lopes, F., Niculescu-Duvaz, I., Niculescu-Duvaz, D., Zambon, A., Davies, L., Johnson, L., Preece, N., Lee, R., Viros, A., Holovanchuk, D., Pedersen, M., McLeary, R., Lorigan, P., Dhomen, N., Fisher, C., Banerji, U., Dean, E., Krebs, M.G., Gore, M., Larkin, J., Marais, R., Springer, C.
Publicado 2021